The new cells prevented the onset of diabetes in an animal model of the disease bringing personalized cell therapy for diabetes closer.
Scientists at the Gladstone Institutes and the University of California, San Francisco (UCSF) have successfully converted human skin cells into fully-functional pancreatic cells. The new cells produced insulin in response to changes in glucose levels, and, when transplanted into mice, the cells protected the animals from developing diabetes in a mouse model of the disease.
The new study, published in Nature Communications, also presents significant advancements in cellular reprogramming technology, which will allow scientists to efficiently scale up pancreatic cell production and manufacture trillions of the target cells in a step-wise, controlled manner. This accomplishment opens the door for disease modeling and drug screening and brings personalized cell therapy a step closer for patients with diabetes.
“Our results demonstrate for the first time that human adult skin cells can be used to efficiently and rapidly generate functional pancreatic cells that behave similar to human beta cells,” says Matthias Hebrok, PhD, director of the Diabetes Center at UCSF and a co-senior author on the study. “This finding opens up the opportunity for the analysis of patient-specific pancreatic beta cell properties and the optimization of cell therapy approaches.”
In the study, the scientists first used pharmaceutical and genetic molecules to reprogram skin cells into endoderm progenitor cells—early developmental cells that have already been designated to mature into one of a number of different types of organs. With this method, the cells don’t have to be taken all the way back to a pluripotent stem cell state, meaning the scientists can turn them into pancreatic cells faster. The researchers have used a similar procedure previously to create heart, brain, and liver cells.
After another four molecules were added, the endoderm cells divided rapidly, allowing more than a trillion-fold expansion. Critically, the cells did not display any evidence of tumor formation, and they maintained their identity as early organ-specific cells.
The scientists then progressed these endoderm cells two more steps, first into pancreatic precursor cells, and then into fully-functional pancreatic beta cells. Most importantly, these cells protected mice from developing diabetes in a model of disease, having the critical ability to produce insulin in response to changes in glucose levels.
“This study represents the first successful creation of human insulin-producing pancreatic beta cells using a direct cellular reprogramming method,” says first author Saiyong Zhu, PhD, a postdoctoral researcher at the Gladstone Institute of Cardiovascular Disease. “The final step was the most unique—and the most difficult—as molecules had not previously been identified that could take reprogrammed cells the final step to functional pancreatic cells in a dish.”
Sheng Ding, PhD, a senior investigator in the Roddenberry Stem Cell Center at Gladstone and co-senior author on the study, adds, “This new cellular reprogramming and expansion paradigm is more sustainable and scalable than previous methods. Using this approach, cell production can be massively increased while maintaining quality control at multiple steps. This development ensures much greater regulation in the manufacturing process of new cells. Now we can generate virtually unlimited numbers of patient-matched insulin-producing pancreatic cells.”
The Latest on: Personalized cell therapy
via Google News
The Latest on: Personalized cell therapy
- OurCrowd leads $8M Series B in Israeli personalized cancer therapy startupon January 20, 2021 at 8:36 pm
Israeli startup OncoHost leverages AI technologies to better understand oncology patients' unique response to treatment, in an effort to combat growing cases of resistance to ...
- OncoHost raises $8 million to develop AI that predicts cancer treatment responseson January 19, 2021 at 1:00 pm
OncoHost, a startup developing an AI platform to predict cancer treatment responses and identify drug targets, has raised $8 million.
- Fujifilm to Establish New Manufacturing and Innovation Center in Massachusettson January 18, 2021 at 10:20 am
2 facility will feature eight cleanrooms with configurations for the production of cell and viral vector products ... Fujifilm Group’s products and services to offer personalized life-altering ...
- Life Science Products Market Growth to register a…on January 17, 2021 at 4:40 am
Long lead times for custom research requirements are expected to hinder ... and reagent systems designed to improve productivity and scalability of cell and gene therapy manufacturing.
- Study may help develop more effective personalized immunotherapy for cancer patientson January 14, 2021 at 10:01 pm
New research from CU Cancer Center member Jing Hong Wang, MD, PhD, and recent University of Colorado Immunology program graduate Rachel Woolaver, PhD, may help researchers develop more effective ...
- Personalized cancer treatments no longer a dream with new medical techon January 14, 2021 at 12:19 am
ADVA X3 is a device that can create life-saving drugs automatically and customized for each individual patient.
- BioMedNewsBreaks Predictive Oncology Inc. (NASDAQ: POAI) Focuses on Multi-Omic Approach to Personalized Treatment Optionson January 13, 2021 at 5:38 am
('AI') to personalized medicine and drug discovery. The company is building a business around an emerging approach to disease prevention ...
- Personalized Stem Cells Announces All Data Collected from FDA Approved Stem Cell Clinical Trial for Knee Arthritison January 12, 2021 at 3:56 pm
Personalized Stem Cells, Inc. announces the final data has been collected for their FDA approved stem cell clinical trial for knee osteoarthritis.
- Performance Cell Manufacturing Completes Stem Cell Manufacturing Contract for Knee Osteoarthritis Clinical Trialon January 12, 2021 at 3:38 pm
Performance Cell Manufacturing recently completed a stem cell manufacturing contract for an FDA approved stem cell clinical trial for knee osteoarthritis.
- New Models in Organoids Market Open New Vistas in Stem Cell Research for Cancer, Global Valuation to Reach US$ 12.8 Bn by 2030: TMRon January 12, 2021 at 6:30 am
PRNewswire/ -- Organoids are stem cell-derived 3D culture systems and are usually derived from induced pluripotent stem cells (iPSCs) and multipotent ...
via Bing News